MITF and melanoma: The MITF p.E318K alteration leads to impaired sumoylation and transcriptional dysregulation and has been associated with both a high nevi count (>200) and increased risk of melanoma.6,7 A separate study2 showed an odds ratio of 4.78 for melanoma, while the odds ratio for combined melanoma and RCC among carriers of this alteration was as high as 14.46.